Patrick M. Moriarty

11.7k total citations · 5 hit papers
109 papers, 4.8k citations indexed

About

Patrick M. Moriarty is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Patrick M. Moriarty has authored 109 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Surgery, 33 papers in Cardiology and Cardiovascular Medicine and 23 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Patrick M. Moriarty's work include Lipoproteins and Cardiovascular Health (69 papers), Lipid metabolism and disorders (21 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (21 papers). Patrick M. Moriarty is often cited by papers focused on Lipoproteins and Cardiovascular Health (69 papers), Lipid metabolism and disorders (21 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (21 papers). Patrick M. Moriarty collaborates with scholars based in United States, United Kingdom and Canada. Patrick M. Moriarty's co-authors include Mary P. McGowan, Cheryl Gibson, James M. Backes, Matthew K. Ito, Janelle F. Ruisinger, Christie M. Ballantyne, Seth J. Baum, Daniel J. Rader, P. Barton Duell and C. Channa Reddy and has published in prestigious journals such as New England Journal of Medicine, Circulation and Nature Medicine.

In The Last Decade

Patrick M. Moriarty

106 papers receiving 4.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

2020 641 citations Seth J. Baum, Erik S.G. Stroes et al. profile →
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

2011 465 citations Christie M. Ballantyne, Daniel J. Rader et al. Journal of clinical lipidology profile →
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

2011 397 citations Christie M. Ballantyne, Daniel J. Rader et al. Journal of clinical lipidology profile →
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

2022 167 citations Michael J. Koren, Patrick M. Moriarty et al. profile →
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

2021 146 citations Christie M. Ballantyne, Patrick M. Moriarty et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick M. Moriarty United States	35	3.1k	1.3k	1.3k	829	737	109	4.8k
Olivier Descamps Belgium	28	2.9k 0.9×	1.5k 1.2×	1.1k 0.9×	841 1.0×	492 0.7×	86	4.5k
Pedro Mata Spain	36	2.7k 0.9×	1.0k 0.8×	830 0.7×	934 1.1×	580 0.8×	119	4.0k
R Češka Czechia	28	3.4k 1.1×	1.3k 1.0×	1.1k 0.8×	742 0.9×	598 0.8×	174	4.8k
Evan A. Stein United States	27	2.6k 0.9×	1.7k 1.3×	818 0.6×	616 0.7×	400 0.5×	59	4.7k
John R. Burnett Australia	36	2.5k 0.8×	1.3k 1.0×	956 0.8×	694 0.8×	1.3k 1.7×	164	4.6k
Atsushi Nohara Japan	37	2.5k 0.8×	1.3k 1.0×	1.1k 0.9×	889 1.1×	877 1.2×	178	4.3k
Jean Bergeron Canada	33	3.3k 1.1×	1.8k 1.4×	1.1k 0.9×	557 0.7×	851 1.2×	81	6.1k
Heiner Greten Germany	33	3.2k 1.0×	1.7k 1.3×	1.2k 1.0×	696 0.8×	824 1.1×	78	5.3k
Anne Langsted Denmark	33	3.0k 1.0×	1.9k 1.5×	1.5k 1.2×	937 1.1×	293 0.4×	77	4.4k
Rodrigo Alonso Spain	33	2.0k 0.7×	808 0.6×	722 0.6×	685 0.8×	501 0.7×	107	3.1k

Countries citing papers authored by Patrick M. Moriarty

Since Specialization

Citations

This map shows the geographic impact of Patrick M. Moriarty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick M. Moriarty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick M. Moriarty more than expected).

Fields of papers citing papers by Patrick M. Moriarty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick M. Moriarty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick M. Moriarty. The network helps show where Patrick M. Moriarty may publish in the future.

Co-authorship network of co-authors of Patrick M. Moriarty

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick M. Moriarty. A scholar is included among the top collaborators of Patrick M. Moriarty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick M. Moriarty. Patrick M. Moriarty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wiegman, Albert, Susanne Greber‐Platzer, Shazia Ali, et al.. (2023). Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia. Circulation. 149(5). 343–353. 41 indexed citations

Deshotels, Matthew R., Ali Agha, Salim S. Virani, et al.. (2022). Genetic Testing for Hypertriglyceridemia in Academic Lipid Clinics: Implications for Precision Medicine—Brief Report. Arteriosclerosis Thrombosis and Vascular Biology. 42(12). 1461–1467. 17 indexed citations

Moriarty, Patrick M., Philippe Gabríel Steg, Jennifer McGinniss, et al.. (2022). Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes. Journal of clinical lipidology. 16(5). 747–756. 2 indexed citations

Koren, Michael J., Patrick M. Moriarty, Joel Neutel, et al.. (2020). Abstract 13951: Safety, Tolerability and Efficacy of Single-dose Amg 890, a Novel Sirna Targeting Lp(a), in Healthy Subjects and Subjects With Elevated Lp(a). Circulation. 142(Suppl_3). 25 indexed citations

Lincoff, A. Michael, Harold Bays, Leslie Cho, et al.. (2020). Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. American Heart Journal. 235. 104–112. 94 indexed citations

O’Dea, Louis, James E. MacDougall, Veronica J. Alexander, et al.. (2019). Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. Journal of the Endocrine Society. 3(12). 2397–2410. 42 indexed citations

Reeskamp, Laurens F., John J.P. Kastelein, Patrick M. Moriarty, et al.. (2018). Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 280. 109–117. 40 indexed citations

Moriarty, Patrick M., et al.. (2018). TREATING LIPOPROTEIN(A)-HYPERPROTEINEMIA AND PROGRESSIVE CARDIOVASCULAR DISEASE WITH LIPID-APHERESIS IN NORTH AMERICA. Journal of the American College of Cardiology. 71(11). A1784–A1784. 1 indexed citations

Aronow, Wilbert S., Amit V. Khera, Stephen L. Kopecky, et al.. (2017). The American Society for Preventive Cardiology Abstracts. Clinical Cardiology. 40(S1). 4–15. 1 indexed citations

10.

Rosenson, Robert S., Steven K. Baker, Maciej Banach, et al.. (2017). Optimizing Cholesterol Treatment in Patients With Muscle Complaints. Journal of the American College of Cardiology. 70(10). 1290–1301. 132 indexed citations

11.

Julius, Ulrich, Mark Milton, Daniel J. Rader, et al.. (2015). Effects of lipoprotein apheresis on PCSK9 levels. Atherosclerosis Supplements. 18. 180–186. 17 indexed citations

12.

Castillo, Sonia Velasco del, et al.. (2013). EFFECT OF LDL-APHERESIS ON HDL-C FUNCTIONALITY. Journal of the American College of Cardiology. 61(10). E1440–E1440. 3 indexed citations

13.

Dufour, Robert, Patrick M. Moriarty, Elisabeth Genestin, et al.. (2012). Abstract 16127: Effect of REGN727/SAR236553 Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Fully Human Monoclonal Antibody in Patients with Elevated Triglycerides/Low High-Density Lipoprotein Cholesterol: Data from Three Phase 2 Studies (NCT:01266876; 01288469; 01288443). Circulation. 126. 2 indexed citations

14.

Backes, James M., Cheryl Gibson, Janelle F. Ruisinger, & Patrick M. Moriarty. (2011). The high-dose rosuvastatin once weekly study (The HD-ROWS). Journal of clinical lipidology. 6(4). 362–367. 10 indexed citations

15.

Backes, James M., Patrick M. Moriarty, Janelle F. Ruisinger, & Cheryl Gibson. (2007). Effects of Once Weekly Rosuvastatin Among Patients With a Prior Statin Intolerance††Conflicts of interest: Dr. Backes is with the Speakers Bureau of Abbott Labs, Abbott Park, Illinois. Dr. Moriarty receives research funding from and is a consultant for B Braun. Dr. Moriarty has also been a consultant for sanofi aventis, Bridgewater, New Jersey, and Reliant Pharmaceuticals, Liberty Corner, New Jersey; with the Speakers Bureaus of Astra Zeneca, Wilmington, Delaware; Abbott Labs, Abbott Park, Illinois; Merck/Schering-Plough, Whitehouse Station, New Jersey, and Takeda Pharmaceuticals, Deerfield, Illinois; and has performed contracted research for Kos Pharmaceuticals, Abbott Park, Illinois; sanofi aventis; Novartis, Basel, Switzerland, HELP Inc., Dover, Delaware; and Kaneka, NY, NY.. The American Journal of Cardiology. 100(3). 554–555. 40 indexed citations

16.

Moriarty, Patrick M. & Cheryl Gibson. (2003). LDL apheresis and its effect on viscosity. 24(6). 321–325. 4 indexed citations

17.

Moriarty, Patrick M. & Cheryl Gibson. (2001). Low-density lipoprotein apheresis in the treatment of atherosclerosis and other potential uses. Current Atherosclerosis Reports. 3(2). 156–162. 8 indexed citations

18.

Moriarty, Patrick M., C. Channa Reddy, & Lynne E. Maquat. (1998). Selenium Deficiency Reduces the Abundance of mRNA for Se-Dependent Glutathione Peroxidase 1 by a UGA-Dependent Mechanism Likely To Be Nonsense Codon-Mediated Decay of Cytoplasmic mRNA. Molecular and Cellular Biology. 18(5). 2932–2939. 177 indexed citations

19.

Moriarty, Patrick M., R. Dimaline, David G. Thompson, & G.J. Dockray. (1997). Characterization of cholecystokininA and cholecystokininB receptors expressed by vagal afferent neurons. Neuroscience. 79(3). 905–913. 111 indexed citations

20.

Boulton, Michael E., Zdeněk Gregor, Patrick M. Moriarty, et al.. (1995). 1445 Growth factor levels in the diabetic vitreous: Correlation with type of diabetes and neovascular activity. Vision Research. 35. S82–S82. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact